Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Britain Courts Anthropic Amid US Defense Department Dispute 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SAN DIEGO, Nov. 22, 2016 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 28th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 29th at 4:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast at http://www.organovo.com. The audio webcast will be archived for 90 days following the conference.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Investor Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 [email protected] Press Contact: Jessica Yingling Little Dog Communications +1 (858) 480-2411 [email protected]
